ParaPRO, LLC is dedicated to developing innovative therapies aimed at addressing the public health challenges posed by human parasites, particularly head lice and scabies. The company’s flagship product, Natroba™ (spinosad) Topical Suspension, 0.9%, is a prescription treatment that has gained recognition as the most frequently prescribed medication in its category. Spinosad, the active compound in Natroba™, is highlighted for its naturally superior mechanism of action (MOA) and is noted for having no known resistance issues, making it a reliable option in an era where many treatments face resistance challenges.

The commitment of ParaPRO to improving family health is evident in their focus on creating effective solutions for infestations that disrupt daily life. Natroba™ was first commercialized in 2011 and has since been made available as an Authorized Generic, enhancing accessibility for patients. The company emphasizes the importance of evidence-based clinical data and insights, ensuring that families and healthcare providers have access to the latest information regarding the treatment of head lice infestations.

United States

ParaPRO LLC is based in Carmel, Indiana. 

At ParaPRO, we specialize in developing therapies for parasite infestations that afflict millions of people every year. While these conditions are common, many treatments are compromised by resistance today, exacerbating the longstanding social and economic implications. Our daily efforts focus on addressing two of the most widespread problems for which new therapies are desperately needed:

HEAD LICE

SCABIES

ParaPRO, LLC

Company Details